Eli Lilly and Company - Total Revenue

Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Total-Revenue" stands at 59.42 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.

Eli Lilly and Company's third quarter result of 17.60 Billion USD for the item "Total Revenue" represents an increase of 13.13 percent compared to it's second quarter result.

Also, Eli Lilly and Company's third quarter result of 17.60 Billion USD for the item "Total Revenue" represents an increase of 53.87 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's third quarter result of 59.42 Billion USD for the item "Total Revenue" represents an increase of 11.57 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 45.41 percent compared to the value the year prior.
The 1 year change in percent is 45.41.
The 3 year change in percent is 103.22.
The 5 year change in percent is 155.97.
The 10 year change in percent is 201.56.

The Serie's long term average value is 26.54 Billion United States Dollars. It's latest available value, on 09/30/2025, is 123.90 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 03/31/2015, to it's latest available value, on 09/30/2025, is +203.52%.
The Serie's change in percent from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0%.